(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of -0.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.75%.
Rigel Pharmaceuticals's revenue in 2025 is $267,921,000.On average, 2 Wall Street analysts forecast RIGL's revenue for 2025 to be $5,037,612,252, with the lowest RIGL revenue forecast at $4,991,782,349, and the highest RIGL revenue forecast at $5,083,442,156. On average, 2 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,193,308,364, with the lowest RIGL revenue forecast at $4,173,122,151, and the highest RIGL revenue forecast at $6,213,494,576.
In 2027, RIGL is forecast to generate $4,561,644,935 in revenue, with the lowest revenue forecast at $4,561,644,935 and the highest revenue forecast at $4,561,644,935.